Royalty Report: Drugs, Cancer, Diagnostic – Collection: 246213

License Grant

The University grants to Licensee, the right and exclusive license in the Territory, to make, have made, use and sell the Licensed Technology in the Field and to practice under the Patent Rights in the Field for the Term.

License Property

The University is the owner by assignment from the inventors of certain Patent Rights, entitled “Cancer prevention and therapy by exclusion of soluble tumor necrosis factor'.

Field of Use

Field shall mean treatment and/or prevention of cancer.

License Grant

University grants an exclusive, world-wide license to make, have made, use, lease, import, offer for sale and sell Licensed Products under Patent Rights, to the extent not prohibited by other patents, in the Field of Use.

License Property

Licensors inventions are Combination Therapy with Opioid Growth Factor and Taxanes for the Treatment of Cancer, and, Combined Therapy with Opioid Growth Factor and Gemcitabine for the Treatment of Cancer.

Field of Use

The Field of Use means development, production, use, and storage of Licensed Products, alone or in combination with other treatments, for the prevention and/or treatment of oncology.

License Grant

In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property

Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.

U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors

Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

Field of Use

Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

License Grant

University granted to the Company an exclusive license to discover, develop, manufacture and sell product in the field of cancer therapy.

License Property

The Product is the utility of serological tumor marker for tumor dynamics monitoring.

Field of Use

Rights are granted for the field of cancer therapy.